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gene expression proﬁle. These discoveries are highly complementary to
those recently reported by a similar study of ALL in AYA in Japan that has
just been published (Yasuda et al., 2016). Single patients with either
MEF2D or ZNF384 fusion translocations have been reported before
(Prima et al., 2005; Gocho et al., 2015) but these are the ﬁrst large stud-
ies describing the signiﬁcance of these fusions in pediatric and adultAcute lymphoblastic leukemia (ALL) is themost common childhood
cancer.Whilemost childrenwith ALL are cured, the prognosis in adoles-
cence and young adults (AYA) as well as older individuals is worse. The
deleterious effects of age on prognosis are partially explained by the de-
crease of the good prognosis initiating chromosomal aberrations (ETV6-
RUNX1 fusions and hyperdiploidy) and an increase of bad prognosis
subtypes (BCR-ABL1 and MLL translocations). Yet as most of the geno-
mic studies were done on childhood ALL, relatively little is known on
AYA and adult ALL. Especially less is known on the genomic characteris-
tics of the “B-others” subgroup – the heterogeneous subgroup of ALLs
lacking the known chromosomal translocations.
The EBioMedicine paper by Liu et al. from the Shanghai Institute of
Hematology (Liu et al., 2016) markedly ﬁlls this void of knowledge.
They performed DNA sequencing of close to 400 children and adults di-
agnostic and remission samples of ALL, identifying 325 recurrent somat-
ic non-synonymousmutations in protein coding genes, a third of which
were never reported before. In addition they performed RNA sequenc-
ing of 78 adults and 94 children and identiﬁed 29 new in-frame fusions.
Adult ALLswere characterizedwithmoremutations especially in epige-
netic and B cell developmental genes and, as previously reported, by
more “B others” ALLs. Yet, reﬂecting probably the different ethnic ori-
gins the frequency of “Philadelphia like” “CRLF2 fusions”ALLs (reviewed
in (Izraeli, 2014)) seems to be lower in the Asian patients.
Non-supervised clustering of gene expression divided the ALLs into
eight subgroups. It will be interesting to learn if these subgroups overlap
with the ones reported by Harvey et al. for an American cohort for pedi-
atric ALLs (Harvey et al., 2010). The most signiﬁcant ﬁndings are the
discoveries of in-frame fusions of MEF2D, ZNF384 and DUX4 genes re-om.2016.04.038.
. This is an open access article underspectively, each creating a separate subgroup characterized by a distinct
ALLs. Herein I will discuss these three important novel subtypes of ALL
in light of the ﬁndings by both groups.
Myocyte Enhancer Factor 2D (MEF2D) is a member of a family of
transcription factors that participate in neuronal development and
myogenesis. The N-terminus ofMEF2Dwas fused to one of several part-
ners, most commonly BCL9, in about 7% of the patients, mostly adoles-
cents. The immunophenotype and gene expression of MEF2D
leukemias were very similar to pre-B ALL caused by the TCF3-PBX1
translocation with high expression of HDAC9, a known target of
MEF2D. Expression of MEF2D fusion in mouse hematopoietic cells
arrested B cell differentiation. Although extra caution should be taken
on assigning prognostic signiﬁcance outside a controlled clinical trial,
both the Chinese and the Japanese papers noted extremely bad progno-
sis to the MEF2D fusion ALLs suggesting a need for better therapies. It
will be interesting to learn if MEF2D pre-B ALL will be sensitive to
Dasatinib, SYK inhibitors or other drugs targeting the pre-B cell receptor
pathway as was recently reported by the Muschen group (Geng et al.,
2015).
The second subgroup is characterized by in-frame fusion of one of
several genes, most notably EP300 or CREBBP, to Zinc Finger 384, detect-
ed in 7–12% of the AYA and older patients. ZNF384 has been shown be-
fore to regulate the expression of genes encoding extracellular matrix
proteins. Unlike theMEF2D fusion leukemias, ZNF384 fusions character-
ized very early pro-B ALL, often CD10 negative with expression of mye-
loid markers and activation of the JAK-STAT pathway. Consistent with
these ﬁndings ectopic expression of the translocations in mouse hema-
topoietic progenitors arrested B cell differentiation and caused
monoblastic leukemias. However, unlike other Pro-B ALLs,most notably
MLL fusion leukemias, it seems from both studies that the prognosis of
this ZNF384 fusion ALLs is relatively good.
The third novel discovery is the subgroup of ALL characterized by
translocations of the Double Homeobox 4 gene, DUX4, into the IgH
enhancer locus. DUX4 is located within a D4Z4 repeat array in the
subtelomeric region of chromosome 4q and encodes the transcriptionalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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associated with autosomal dominant facioscapulohumeral muscular
dystrophy (FSHD). The Tokyo group discovered that the translocation
to the IgH locus, presented in 10 of 70 AYA patients with ALL, led to
high expression of DUX4 with modiﬁed C terminus. Signiﬁcantly, they
demonstrated that transduction of mouse pro-B progenitors with
DUX4-IGH fusion gene caused B cell leukemia in mice. They also discov-
ered the translocation in the B ALL cell line NALM6 and showed that
DUX4 was necessary for its growth and survival (Yasuda et al., 2016).
In addition to the newly discovered DUX4 translocation, NALM6
contains a microdeletion in the ERG gene (Zhang et al., 2011). Interest-
ingly the Shanghai group discovered that nearly all the DUX4 ALLs had
also ERG deletions. Microdeletionswithin the ERG gene have been iden-
tiﬁed in about 5%of childhoodALL. They are characterizedwith aberrant
CD2 expression and despite common presence of IKZF1 deletions they
have excellent prognosis. Themicrodeletionswithin ERG are often asso-
ciated with aberrant transcripts of ERG that have been suggested to be
oncogenic. Yet these aberrant transcripts are not always expressed
and ERG deletions are often subclonal and disappear in relapse
(Clappier et al., 2014). These mysterious observations have led to the
suggestion that “ERG deletions” ALLsmay actually be caused by another
driving genomic aberration. The ﬁndings by Liu et al. that the recently
discovered oncogenic DUX4-IgH cryptic translocations almost always
occur in ERG deleted leukemias suggest either that DUX4 is the onco-
genic driving event or that DUX4 cooperates with ERG aberrant isoform
in the leukemogenesis process.
Together, the two comprehensive genomic studies from China and
Japan have greatly enhanced our understanding of ALL in AYA and
have identiﬁed three novel ALL subgroups with distinct genotype,
immunophehnotype and prognostic signiﬁcance as well as suggestions
for potential therapies.Disclosure
Funding for B-ALL research in the author's laboratory is provided by
Israel Science Foundation (grant number 815/14).References
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